Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today announced.
Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a.